Literature DB >> 11456309

PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A.

L Nobbio1, G Mancardi, M Grandis, G Levi, U Suter, K A Nave, A J Windebank, M Abbruzzese, A Schenone.   

Abstract

Charcot-Marie-Tooth 1A (CMT1A) neuropathy is caused by duplication of the peripheral myelin protein 22 (PMP22) gene, leading to protein overexpression. Although this protein has a role in regulating Schwann cell growth and peripheral myelin compaction, how altered concentrations of PMP22 impair myelination is unknown. We established dorsal root ganglia (DRG) cultures from a transgenic rat overexpressing PMP22 (PMP22tg) to study the behavior of PMP22tg Schwann cells in early stages of development and myelination. We used reverse transcriptase-polymerase chain reaction and light and electron microscopy to study PMP22 expression and myelin formation. Myelin ultrastructure was evaluated in sural nerves from CMT1A patients to compare experimental and human findings. PMP22tg DRG cultures contained a greater number of internodes devoid of myelin, in the absence of remyelination, and increased periodicity of myelin lamellae compared with normal cultures. Widening of myelin lamellae was also observed in CMT1A biopsy specimens. Our results suggest that both functions of PMP22, in regulating Schwann cell differentiation and contributing to peripheral myelin compaction, are affected by its overexpression. The presence of similar myelin abnormalities in PMP22tg cultures and human nerves emphasizes the importance of developing in vitro models of hereditary neuropathies to study their underlying pathomechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456309     DOI: 10.1002/ana.1034

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  Animal models of Charcot-Marie-Tooth disease type 1A.

Authors:  M W Sereda; K-A Nave
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug discovery for peripheral neuropathies.

Authors:  Giorgia Melli; Ahmet Höke
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

3.  P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy.

Authors:  Lucilla Nobbio; Laura Sturla; Fulvia Fiorese; Cesare Usai; Giovanna Basile; Iliana Moreschi; Federica Benvenuto; Elena Zocchi; Antonio De Flora; Angelo Schenone; Santina Bruzzone
Journal:  J Biol Chem       Date:  2009-06-22       Impact factor: 5.157

4.  Hyccin, the molecule mutated in the leukodystrophy hypomyelination and congenital cataract (HCC), is a neuronal protein.

Authors:  Elisabetta Gazzerro; Simona Baldassari; Caterina Giacomini; Veronica Musante; Floriana Fruscione; Veronica La Padula; Roberta Biancheri; Sonia Scarfì; Valeria Prada; Federica Sotgia; Ian D Duncan; Federico Zara; Hauke B Werner; Michael P Lisanti; Lucilla Nobbio; Anna Corradi; Carlo Minetti
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

5.  A novel transgenic mouse model of Chinese Charcot-Marie-Tooth disease type 2L.

Authors:  Ruxu Zhang; Fufeng Zhang; Xiaobo Li; Shunxiang Huang; Xiaohong Zi; Ting Liu; Sanmei Liu; Xuning Li; Kun Xia; Qian Pan; Beisha Tang
Journal:  Neural Regen Res       Date:  2014-02-15       Impact factor: 5.135

6.  Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.

Authors:  Ilya Chumakov; Aude Milet; Nathalie Cholet; Gwenaël Primas; Aurélie Boucard; Yannick Pereira; Esther Graudens; Jonas Mandel; Julien Laffaire; Julie Foucquier; Fabrice Glibert; Viviane Bertrand; Klaus-Armin Nave; Michael W Sereda; Emmanuel Vial; Mickaël Guedj; Rodolphe Hajj; Serguei Nabirotchkin; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

7.  Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy.

Authors:  R Fledrich; T Abdelaal; L Rasch; V Bansal; V Schütza; B Brügger; C Lüchtenborg; T Prukop; J Stenzel; R U Rahman; D Hermes; D Ewers; W Möbius; T Ruhwedel; I Katona; J Weis; D Klein; R Martini; W Brück; W C Müller; S Bonn; I Bechmann; K A Nave; R M Stassart; M W Sereda
Journal:  Nat Commun       Date:  2018-08-02       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.